Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatmentYang Liu, Stefan K. Barta|American Journal of Hematology|2019Cited by 503
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Marco Ruella, Joseph A. Fraietta et al.|Nature Medicine|2024Cited by 254
Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomasGuido Ghilardi, Stephen J. Schuster, Elise A. Chong et al.|Annals of Oncology|2022Cited by 95
Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphomaNicole Thomas, Stefania Pittaluga, Kostiantyn Dreval et al.|Blood|2022Cited by 86
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort studyNarendranath Epperla, Reem Karmali, Lei Feng et al.|Journal of Hematology & Oncology|2023Cited by 52